Man Group PLC Poseida Therapeutics, Inc. Transaction History

Man Group PLC

$37.6 Billion
Q2 2024

A detailed history of Man Group PLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 80,576 shares of PSTX stock, worth $297,325. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,576

Previous 79,637 1.18%

Holding current value

$297,325

Previous $254,000 7.48%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.0 - $3.46 $1,878 - $3,248	939 Added 1.18%	80,576 $235,000
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $219,798 - $328,900	79,637 New	79,637 $254,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.4 $599 - $1,227	-361 Reduced 1.13%	31,450 $55,000
Q1 2023 May 15, 2023	BUY	$3.08 - $8.73 $12,775 - $36,212	4,148 Added 14.99%	31,811 $97,000
Q4 2022 Feb 14, 2023	BUY	$3.33 - $6.38 $52,104 - $99,827	15,647 Added 130.22%	27,663 $146,000
Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $29,198 - $54,192	12,016 New	12,016 $42,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

39.2M

Call Options Held

417K

Put Options Held

42.7K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $317M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account